Emerphed FDA Approval History
Last updated by Judith Stewart, BPharm on June 24, 2020.
FDA Approved: Yes (First approved April 17, 2020)
Brand name: Emerphed
Generic name: ephedrine sulfate
Dosage form: Injection
Company: Nexus Pharmaceuticals, Inc.
Treatment for: Hypotension
Emerphed (ephedrine sulfate) is a ready-to-use formulation of the approved pressor agent ephedrine indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
- Emerphed is a pre-mixed formulation that does not require any dilution before administration. Pre-mixed formulations save staff valuable time in the OR setting, and also reduce the potential for preparation error and waste.
- Emerphed is administered as an intravenous bolus injection.
- Common adverse reactions include nausea, vomiting, and tachycardia.
Development timeline for Emerphed
|Apr 21, 2020||Approval FDA Approves Emerphed (ephedrine sulfate) Ready-to-Use Injection for Hypotension During Anesthesia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.